Compare iShares MSCI India ETF (INDA) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Nuwellis Inc — how do they compare? iShares MSCI India ETF trades at $46.03 (market cap $5.73B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: iShares MSCI India ETF is far larger — about 2604.5× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 6,797,522). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 58 Days and Nuwellis Inc for 26 Days on average.
| INDA | NUWE | |
|---|---|---|
Market Cap | $5.73B | $2.20M |
Volume | 6,797,522 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $146.65 |
52-Week Low | $45.42 | $0.68 |
Typical Hold Time | 58 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $46.03, down 0.2% on the day, with a bearish technical signal driven by moving averages and oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. Recent news highlights India's economic growth amid sector-specific challenges, including energy security concerns and pharmaceutical export hurdles, which may influence the ETF's underlying holdings.
The outlook remains cautious due to technical weakness and macroeconomic headwinds in India. Opportunities exist if oversold conditions reverse, but risks include regulatory tensions and sector volatility. Investors should await updated financials for a clearer fundamental picture.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
